Evidence map›Paper›PMID 37059703›Full record

ArticleNature communications2023

Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Christopher Jonkergouw, Ngong Kodiah Beyeh, Ekaterina Osmekhina, Katarzyna Leskinen, S Maryamdokht Taimoory, Dmitrii Fedorov, Eduardo Anaya-Plaza, Mauri A Kostiainen, John F Trant, Robin H A Ras and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Advances in BODIPY Derivatives for Antibacterial Phototherapy.Angewandte Chemie (International ed. in English) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Christopher JonkergouwAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland. chris@jonkergouw.nl.ORCID 0000-0001-9445-9864
Ngong Kodiah BeyehOakland University, Department of Chemistry, 146 Library Drive, Rochester, MI, 48309-4479, USA.ORCID 0000-0003-3935-1812
Ekaterina OsmekhinaAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland.ORCID 0000-0002-5756-9877
Katarzyna LeskinenUniversity of Helsinki, Translational Immunology Research Program, Haartmaninkatu 8, 0014, Helsinki, Finland.
S Maryamdokht TaimooryUniversity of Windsor, Department of Chemistry and Biochemistry, Windsor, ON, N9B 3P4, Canada.
Dmitrii FedorovAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland.
Eduardo Anaya-PlazaAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland.ORCID 0000-0001-9944-6907
Mauri A KostiainenAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland.ORCID 0000-0002-8282-2379
John F TrantUniversity of Windsor, Department of Chemistry and Biochemistry, Windsor, ON, N9B 3P4, Canada.ORCID 0000-0002-4780-4968
Robin H A RasAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland.ORCID 0000-0002-2076-242X
Päivi SaavalainenUniversity of Helsinki, Translational Immunology Research Program, Haartmaninkatu 8, 0014, Helsinki, Finland. paivi.saavalainen@helsinki.fi.
Markus B LinderAalto University, School of Chemical Engineering, Department of Bioproducts and Biosystems, Kemistintie 1, 02150, Espoo, Finland. markus.linder@aalto.fi.ORCID 0000-0002-7271-6441
Aalto University · FIUniversity of Helsinki · FIOakland University · USUniversity of Michigan · USUniversity of Windsor · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limited diversity in targets of available antibiotic therapies has put tremendous pressure on the treatment of bacterial pathogens, where numerous resistance mechanisms that counteract their function are becoming increasingly prevalent. Here, we utilize an unconventional anti-virulence screen of host-guest interacting macrocycles, and identify a water-soluble synthetic macrocycle, Pillar[5]arene, that is non-bactericidal/bacteriostatic and has a mechanism of action that involves binding to both homoserine lactones and lipopolysaccharides, key virulence factors in Gram-negative pathogens. Pillar[5]arene is active against Top Priority carbapenem- and third/fourth-generation cephalosporin-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, suppressing toxins and biofilms and increasing the penetration and efficacy of standard-of-care antibiotics in combined administrations. The binding of homoserine lactones and lipopolysaccharides also sequesters their direct effects as toxins on eukaryotic membranes, neutralizing key tools that promote bacterial colonization and impede immune defenses, both in vitro and in vivo. Pillar[5]arene evades both existing antibiotic resistance mechanisms, as well as the build-up of rapid tolerance/resistance. The versatility of macrocyclic host-guest chemistry provides ample strategies for tailored targeting of virulence in a wide range of Gram-negative infectious diseases.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBiofilmsCalixarenesDrug Resistance, Multiple, BacterialHomoserineLactonesMicrobial Sensitivity TestsPseudomonas aeruginosaQuaternary Ammonium CompoundsAnti-Bacterial AgentsCalixarenesHomoserineLactonespillar(5)areneQuaternary Ammonium Compounds

Identifiers

PMID37059703
PMCPMC10104825
OpenAlexW4365509851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.